Paediatric diabetes centres will have received the list of approved providers of HCL systems under the NHSE procurement framework. Medtrum is included on the list but centres may not be aware that at present, Medtrum has also not provided any published evidence of safety and efficacy on the use of the system in children, despite multiple requests for them to do so. The Diabetes Technology Network (DTN) have also issued a statement raising their concerns around the inclusion of the Medtrum HCL in the list of approved systems. In line with the DTN, the BSPED and ACDC (Association of Children’s Diabetes Clinicians) do not recommend that the Medtrum HCL system should be used for children and young people with diabetes in the UK until published evidence of its safety and efficacy is provided.

Dr Tabitha Randell, BSPED Chair
Dr Fiona Regan, ACDC Chair

This position statement can be found on our website on the following link should you need to refer colleagues to it: https://www.bsped.org.uk/clinical-resources/position-statements/#Medtrum